Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of many tumor types. and durable responses can be observed in select populations. However. patients may exhibit significant immune-related adverse events (irAEs) that may lead to morbidity. https://www.opheliasmuse.com/